Vali Barsan, MD is an oncologist and bioengineer focused on the clinical development and implementation of novel diagnostics in early cancer detection and personalized medicine approaches. Dr. Barsan obtained his BS in Bioengineering at UC San Diego Jacobs School of Engineering and joined Illumina as a process development engineer to optimize next generation sequencing tools. He earned his MD at Baylor College of Medicine where he studied the biology of cancer metastasis through molecular techniques at MD Anderson Cancer Center. Dr. Barsan completed residency in Pediatrics at UC San Diego where he was a member of the weekly Molecular Tumor Board at Moores Cancer Center. He then completed fellowship in Pediatric Hematology/Oncology and Stem Cell Transplantation at Stanford University School of Medicine where his research focus spanned biomarkers for Phase 1 CAR T cell therapy, molecular monitoring in leukemia therapy, and clinical CRISPR/Cas safety workflows. Dr. Barsan continues to develop and translate molecular technologies in oncology to implement personalized therapy at commercial scale and reveal mechanisms of effective cancer immunity. Since 2017 as a consultant to SoftBank, Dr. Barsan has led numerous life science investments in life science tools, molecular diagnostics, and next generation medicines including Umoja Biopharma, Neuron23, Arsenal Bio, Guardant, InterVenn, Synthego, Tessera Therapeutics, Vividion, Repertoire Immune Medicines, Lumicks, Leyden Labs, EQRx, and Pacific Biosciences / Omniome.